EP1253930A2 - Method and compositions for treating hepatocellular cancer - Google Patents
Method and compositions for treating hepatocellular cancerInfo
- Publication number
- EP1253930A2 EP1253930A2 EP01910587A EP01910587A EP1253930A2 EP 1253930 A2 EP1253930 A2 EP 1253930A2 EP 01910587 A EP01910587 A EP 01910587A EP 01910587 A EP01910587 A EP 01910587A EP 1253930 A2 EP1253930 A2 EP 1253930A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- seq
- residues
- human
- peptide
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims abstract description 69
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 206010073071 hepatocellular carcinoma Diseases 0.000 title claims description 52
- 208000014018 liver neoplasm Diseases 0.000 title description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 180
- 210000004027 cell Anatomy 0.000 claims abstract description 105
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 61
- 201000011510 cancer Diseases 0.000 claims abstract description 57
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims abstract description 51
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims abstract description 51
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 32
- 230000028993 immune response Effects 0.000 claims abstract description 22
- 241000124008 Mammalia Species 0.000 claims abstract description 17
- 230000003213 activating effect Effects 0.000 claims abstract description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 10
- 210000004443 dendritic cell Anatomy 0.000 claims description 51
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 47
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 8
- 230000000063 preceeding effect Effects 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 85
- 208000030062 persistent idiopathic facial pain Diseases 0.000 description 65
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 63
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 26
- 150000001413 amino acids Chemical group 0.000 description 14
- 230000003053 immunization Effects 0.000 description 14
- 238000002649 immunization Methods 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 101150106931 IFNG gene Proteins 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 102000004388 Interleukin-4 Human genes 0.000 description 7
- 108090000978 Interleukin-4 Proteins 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000011510 Elispot assay Methods 0.000 description 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 6
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 229940028885 interleukin-4 Drugs 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 210000004988 splenocyte Anatomy 0.000 description 5
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 4
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 3
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 3
- 101000848653 Homo sapiens Tripartite motif-containing protein 26 Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000004013 groin Anatomy 0.000 description 3
- 102000046101 human AFP Human genes 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 229960000520 diphenhydramine Drugs 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002516 postimmunization Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229940072651 tylenol Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 1
- 101710197836 HLA class I histocompatibility antigen, alpha chain G Proteins 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 101000827785 Homo sapiens Alpha-fetoprotein Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 206010033109 Ototoxicity Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 101100460554 Triticum aestivum AFP-A1 gene Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- AFVLVVWMAFSXCK-VMPITWQZSA-N alpha-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(\C#N)=C\C1=CC=C(O)C=C1 AFVLVVWMAFSXCK-VMPITWQZSA-N 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000014828 interferon-gamma production Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 231100000262 ototoxicity Toxicity 0.000 description 1
- 230000007255 peripheral T cell response Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46448—Cancer antigens from embryonic or fetal origin
- A61K39/464481—Alpha-feto protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/53—Liver
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- Hepatocellular carcinoma is the most common type of primary liver cancer, having a global incidence of approximately 1.2 million cases per year. In some areas of the world, such as Southeast Asia and Subsahara Africa, hepatocellular carcinoma is one of the most common types of malignancies. The high frequency of the disease appears to be related to the high incidence of viral hepatitis in these regions.
- Curative therapy of hepatocellular carcinoma is currently limited to individuals with nonmetastatic disease and involves surgical resection of the tumor with or without liver transplantation. Even surgical resection and transplantation, however, do not cure most tumors because of recurrence after resection. Chemotherapeutic approaches to treatment have been largely ineffective.
- the treatment should ideally be suitable for use in lesser developed countries that have the highest incidence of the disease. Further, the treatment should be appropriate for use in individuals with unresectable tumors and with metastatic disease.
- the present invention is a method for preventing or for treating cancer in a mammal, where the cancer cells express at least a part of an alpha fetoprotein molecule at the cell surface.
- the method comprises the step of creating an immune response in the mammal to at least part of the amino acid sequence of an alpha fetoprotein molecule where the immune response comprises activating alpha fetoprotein peptide specific T lymphocytes against the cancer cells.
- the alpha fetoprotein peptide specific T lymphocytes are cytotoxic T lymphocytes.
- the alpha fetoprotein molecule is SEQ ID NO:2.
- the alpha fetoprotein molecule is selected from the group consisting of residues 137-145 of SEQ ID NO:2, residues 158-166 of SEQ ID NO:2, residues 325-334 of SEQ ID NO:2 and residues 542-550 of SEQ ID NO:2.
- the cancer is hepatocellular carcinoma.
- the mammal is a human.
- the step of creating an immune response comprises administering to the mammal one or more than one composition including a peptide comprising at least part of the alpha fetoprotein amino acid sequence.
- the peptide is selected from the group consisting of residues 137-145 of SEQ ID NO:2, residues 158-166 of SEQ ID NO:2, residues 325-334 of SEQ ID NO:2, and residues 542-550 of SEQ ID NO: 2.
- the peptide is selected from the group consisting of residues 1-9 of SEQ ID NO:2, residues 178-186 of SEQ ID NO:2, residues 218-226 of SEQ ID NO:2, residues 235-243 of SEQ ID NO:2, residues 306-315 of SEQ ID NO:2, residues 485-493 of SEQ ID NO:2, residues 492-500 of SEQ ID NO:2, residues 507-516 of SEQ ID NO:2, residues 547-556 of SEQ ID NO:2 and residues 555-563 of SEQ ID NO:2.
- the step of creating an immune response comprises administering to the mammal one or more than one composition including dendritic cells pulsed with one or more than one peptide that forms at least part of the amino acid sequence of SEQ ID NO:2.
- the step of creating an immune response comprises administering to the mammal one or more than one composition including dendritic cells transduced with a recombinant adenoviral vector encoding alpha fetoprotein.
- the present invention is a method for preventing or for treating hepatocellular carcinoma in a human, where the cancer cells express at least a part of an alpha fetoprotein molecule at the cell surface, the method comprising the step of activating alpha fetoprotein cytotoxic T lymphocytes against the cancer cells to at least part of the amino acid sequence of SEQ ID NO: 2 by administering to the human one or more than one composition including a peptide selected from the group consisting of residues 137-145 of SEQ ID NO:2, residues 158-166 of SEQ ID NO:2 and residues 325-334 of SEQ ID NO:2.
- the present invention is a method for preventing or for treating hepatocellular carcinoma in a human, where the cancer cells express at least a part of an alpha fetoprotein molecule at the cell surface, the method comprising the step of activating alpha fetoprotein cytotoxic T lymphocytes against the cancer cells to at least part of the amino acid sequence of SEQ ID NO: 2 by administering to the human one or more than one composition including a peptide selected from the group consisting of residues 542-550 of SEQ ID NO:2.
- the present invention is a method for preventing or for treating hepatocellular carcinoma in a human, where the cancer cells express at least a part of an alpha fetoprotein molecule at the cell surface, the method comprising the step of activating alpha fetoprotein cytotoxic T lymphocytes against the cancer cells to at least part of the amino acid sequence of SEQ ID NO:2 by administering to the human one or more than one composition including a peptide selected from the group consisting of residues 1-9 of SEQ ID NO:2, residues 178-186 of SEQ ID NO:2, residues 218-226 of SEQ ID NO:2, residues 235- 243 of SEQ ID NO:2, residues 306-315 of SEQ ID NO:2, residues 485-493 of SEQ ID NO:2, residues 492-500 of SEQ ID NO:2, residues 507-516 of SEQ ID NO:2, residues 547- 556 of SEQ ID NO:2 and residues 555-563 of SEQ ID NO:2.
- the present invention is a method for preventing or for treating hepatocellular carcinoma in a human, where the cancer cells express at least a part of an alpha fetoprotein molecule at the cell surface, the method comprising the step of activating alpha fetoprotein cytotoxic T lymphocytes against the cancer cells to at least part of the amino acid sequence of SEQ ID NO:2 by administering to the human one or more than one composition including dendritic cells pulsed with one or more than one peptide that forms at least part of the amino acid sequence of SEQ ID NO:2.
- the one or more than one peptide are selected from the dendritic cells pulsed with one or more than one peptide is selected from the group consisting of residues 137-145 of SEQ ID NO:2, residues 158-166 of SEQ ID NO:2, residues 325-334 of SEQ ID NO:2, and residues 542-550 of SEQ ID NO:2.
- the present invention is a method for preventing or for treating hepatocellular carcinoma in a human, where the cancer cells express at least a part of an alpha fetoprotein molecule at the cell surface, the method comprising the step of activating alpha fetoprotein cytotoxic T lymphocytes against the cancer cells to at least part of the amino acid sequence of SEQ ID NO:2 by administering to the human one or more than one composition including dendritic cells transduced with a recombinant adenoviral vector encoding alpha fetoprotein.
- the present invention is an isolated peptide useful for preventing or for treating cancer selected from the group consisting of residues 137-145 of SEQ ID NO:2, residues 158-166 of SEQ ID NO:2, and residues 325-334 of SEQ ID NO:2.
- the present invention is a composition for preventing or for treating cancer comprising one or more than one peptide selected from the group consisting of residues 137-145 of SEQ ID NO:2, residues 158-166 of SEQ ID NO:2, and residues 325- 334 of SEQ ID NO:2 an amount sufficient to create an immune response to alpha fetoprotein in a mammal.
- the composition can additionally comprising an adjuvant.
- the present invention is a method for preventing or for treating cancer in a human comprising the step of administering to the human one of these peptides or one of these compositions.
- the present invention also includes means for preventing or for treating cancer comprising one or more than one peptide selected from the group consisting of residues 137- 145 of SEQ ID NO:2, residues 158-166 of SEQ ID NO:2, residues 325-334 of SEQ ID NO:2 and residues 542-550 of SEQ ID NO:2.
- the present invention is an isolated peptide useful for preventing or for treating cancer having a sequence according to residues 542-550 of SEQ ID NO:2.
- the present invention is a composition for preventing or for treating cancer comprising a peptide having a sequence according to residues 542-550 of SEQ ID NO:2.
- the composition can additionally comprising an adjuvant.
- the present invention is a method for preventing or for treating cancer in a human comprising the step of administering to the human this peptides or one of these compositions.
- the present invention also includes means for preventing or for treating cancer comprising a peptide having a sequence according to residues 542-550 of SEQ ID NO:2.
- the present invention is a group of peptides that, alone or in combination, can be used to treat hepatocellular carcinoma.
- the present invention is a method for preventing or for treating hepatocellular carcinoma by administering one or more than one peptides of the present invention, alone or in combination, or a composition comprising one or more than one peptide of the present invention.
- the present invention is a method for preventing or for treating hepatocellular carcinoma by administering dendritic cells pulsed with one or more than one peptide of the present invention, or transduced with a recombinant adenoviral (AdV) vector encoding alpha fetoprotein.
- AdV recombinant adenoviral
- hepatocellular carcinomas reactivate alpha fetoprotein expression.
- Both the murine and human T cell repertoires can recognize AFP-derived peptide epitopes in the context of MHC class I. Therefore, despite being exposed to high plasma levels of this oncofetal protein during embryonic development, not all of AFP- specif c T cells are deleted during the ontogeny of the immune system.
- the present invention involves the determination of the identity of peptides derived from human alpha fetoprotein, SEQ ID NO:2, which when presented in the context of HLA- A*0201, are recognized by the human T cell repertoire.
- SEQ ID NO:2 human alpha fetoprotein
- Table 1 four AFP-derived peptides were identified, designated the "dominant" peptides. They are PLFQVPEPV, hAFP 137 . I45 , residues 137-145 of SEQ ID NO:2; FMNKFIYEI, hAFP 158 . 166 , residues 158-166 of SEQ ID NO:2; GLSPNLNRFL, hAFP 325 .
- Each of the dominant peptides stabilized HLA-A*0201 on T2 cells in a concentration- dependent class I binding assay. The peptides were stable for 2 to 6 hours in an off-kinetics assay. Additionally, each dominant peptide induced peptide-specific T cells in vitro from several normal HLA-A*0201 donors.
- these hAFP peptide-specific T cells were also capable of recognizing HLA-A*0201 +/AFP positive tumor cells in both cytotoxicity assays and IFNg ELISPOT assays. This information is summarized TABLE 1 SUMMARY OF THE DOMINANT PEPTIDES
- activation of these T cells can be achieved by presenting these dominant peptides in an immunostimulatory context, including presentation by professional antigen presenting dendritic cells.
- Dendritic cells transduced with a recombinant adenoviral (AdV) vector encoding alpha fetoprotein cDNA, SEQ ID NO: 1, will process and present the four dominant peptide epitopes in the context of MHC, and will also induce AFP-specific T cell activation.
- AdV adenoviral
- AFP peptide-stimulated human and HLA-A*0201/K b mouse T cell responses recognized hAFP- engineered targets and, to a lesser extent, naturally AFP-expressing human hepatocellular carcinoma cells.
- mass spectrometry was used to identify at least three AFP epitopes from complex mixtures of peptides eluted from HLA-A*0201 + HCC cells.
- compositions and methods of the present invention are disclosed primarily in the context of using one or more than one of the dominant peptides, hAFP 137 . 145 , residues 137-145 of SEQ ID NO:2; hAFP, 5g . 1(S6 , residues 158-166 of SEQ ID NO:2; AFP 325 _ 334 , residues 325-334 of SEQ ID NO:2; and residues 542-550 of SEQ ID NO:2, it is within the scope of the present invention to use one or more than one of the ten subdominant peptides in place or in conjunction with one or more than one of the four dominant peptides.
- peptide sequences from hAFP, SEQ ID NO:2, (Genbank accession numbers: J00077, J00076 and V01514) were identified that would potentially bind to HLA-A*0201. These peptides have between nine or ten amino acids in length, the amino acids isoleucine, leucine and methionine in position 2, or can have the amino acids isoleucine, leucine and valine in peptide positions 9 or 10, depending on the peptide length, or both. Seventy-four such peptides were identified using the University of Wisconsin Genetics Computer Group Program "find patterns" to screen the hAFP sequence, SEQ ID NO:2. Each of the 74 peptides were synthesized using standard techniques.
- T2 T2 (TAP deficient) cells that had been incubated at room temperature the previous night to increase cell surface MHC class I molecule expression were then incubated overnight with each peptide over a range of peptide concentrations, from 0.1 mM-100 mM. Stability of HLA-A*0201 was assayed by flow cytometry after staining the cells with anti-HLA-A2 antibody (BB7.2) and goat antimouse- FITC. The HLA-A*0201 strongly binding Flu matrix peptide (aa 58-66) (Flu) was used as a positive control.
- HLA-A*0201 LCL were stripped with a mild pH3.2 citrate-phosphate acid buffer.
- Each peptide was immediately pulsed onto cells at 200 mM for 1 hour in the presence of b2 microglobulin at 3 ug/ml at room temperature. Excess peptide was washed off and the cells were incubated at 37°C for 0, 2, 4 and 6 hours. Cells were washed at the end of each time point and stained for cell surface HLA-A2 expression, then analyzed by flow cytometry.
- the peptide-MHC class I complex was considered stable if the mean fluorescence intensity increased at least 1.5-fold from cells that were stripped but not pulsed with peptide. All four dominant peptides were stable for 2 to 6 hours in the off-kinetics assay.
- the four dominant peptides were then subjected to additional immunological and physicochemical studies. These studies included in vitro studies where (1) peptides were used to make AFP peptide-specific human T cell cultures which were both peptide specific and recognized native AFP-expressing cells; (2) AdVhAFP-transduced dendritic cells were used to make AFP specific human T cells which recognized AFP positive cells, as well as AFP negative cells pulsed with the dominant peptides; and in vivo studies where (1) transgenic mice which were immunized with peptides had splenocytes that recognized peptides and AFP positive cells; and (2) AdVhAFP/DC immunized mice recognized AFP positive cells and as well as AFP negative cells pulsed with the dominant peptides.
- the dominant peptides are immunogenic, that AFP itself is immunogenic, that the dominant peptides are naturally processed and presented on the surface of AFP positive cells and that both AFP/DC or the dominant peptides can be used to generate AFP-specific T cells which make cytokines and kill AFP positive cells. Further, mass spectroscopy was used to physically identify the AFP peptides from the surface of AFP positive hepatocellular carcinoma cells.
- the AFP peptide-specific bulk T cells also recognized both AFP negative stably transfected and AdVhAFP-transduced HLA-A*0201 melanoma cells (M202) compared to unmodified or empty AdVRR5 transduced parental cells as shown by an increased frequency of IFNg-producing AFP-specific T cells.
- M202 AdVhAFP-transduced HLA-A*0201 melanoma cells
- AdVRR5 transduced parental cells as shown by an increased frequency of IFNg-producing AFP-specific T cells.
- HLA-A*0201 + naturally AFP-expressing hepatocellular carcinoma cell line HepG2 (compared to the HLA-A2-/AFP positive HCC line Hep3B), both cytotoxicity and ELISPOT assays were performed.
- CTL were generated from AdV transduced dendritic cells.
- dendritic cells prepared from PBMC incubated with GM-CSF and IL-4 were transduced with AdVhAFP or AdVMARTl at a multiplicity of infection (moi) of 1,000 for 2 hours.
- Transduced dendritic cells were washed, irradiated and plated at 1-2 xlO 5 cells/ml to serve as stimulators for CTL generation.
- Autologous non-adherent cells were depleted of CD4, CD 14, CD 19 and CD56+ cells by magnetic bead depletion to prepare CD8+ enriched responder cells (population generally 80% CD8+, not shown).
- the CD8+ cells were plated with the transduced dendritic cells at 2 x 10 6 cells/ml, in 5 % autologous medium plus IL-7 at 10-25 ng/ml. Cultures were supplemented with IL-2 at 10 U/ml every 3-4 days.
- CTL were restimulated weekly with fresh, autologous AdV-transduced dendritic cells at a ratio of 1 dendritic cell to 10-20 CD8+ CTL. Most cultures were phenotyped for CD4+ and CD8+ cells on a weekly basis. Each dominant peptide induced peptide-specific T cells in vitro from several normal HLA-A*0201 donors. Because Ad Vh AFP/DC in vitro stimulated human T cells specifically recognized hAFP-transfected targets in both CTL and ELISPOT assays, the four dominant peptides were next studied to determine whether they were specifically recognized by the AdVhAFP/DC stimulated T cells.
- CD8-enriched T cells stimulated weekly with AdVhAFP/DC were tested for both cytotoxicity and the frequency of hAFP peptide- specific IFNg cytokine producing cells.
- AdVhAFP/DC T cell cultures were cytotoxic for JY cells pulsed with each of the four AFP peptides, indicating that CTL to these peptides could be expanded from peripheral blood of normal donors.
- the AdVhAFP/DC stimulated T cell cultures also had a low frequency of cytokine- producing cells which recognized the A*0201+/AFP positive hepatocellular carcinoma line HepG2 but not the A*0201-/AFP positive HCC line Hep3B.
- T lymphocytes synthesizing the Thl cytokines IFNg and TNFa were detected, while the Th2 cytokine IL-4 was not detected.
- IL-10 was also detected when the hepatocellular carcinoma lines were plated without T cells, indicating that production of this cytokine was tumor cell-derived.
- HLA-A*0201/K b transgenic mice were used to screen the 74 peptides to determine whether any of these peptides were immunogenic, and naturally processed and presented in the context of HLA-A*0201 as follows.
- HLA-A*0201/K b transgenic female mice were originally purchased from Harlan-Sprague Dawley (Indianapolis, IN US), and are currently bred by the animal facility of the Dept. of Radiation Oncology at University of California, Los Angeles.
- mice received 100 ⁇ g AFP or control peptide emulsified 1: 1 in complete Freund's adjuvant subcutaneously. After immunization with each peptide emulsified in complete Freund's adjuvant, draining lymph node cells produced IFNg upon recognition of cells stably transfected with hAFP. Furthermore, alpha fetoprotein peptide- specific T cells could be identified in the spleens of mice immunized with dendritic cells transduced with an AFP-expressing adenovirus (AdVhAFP). Thus, the four dominant peptides are naturally processed and presented in the context of class I and are immunogenic.
- AdVhAFP AFP-expressing adenovirus
- HLA-A*0201/K b mice were immunized with each dominant peptide pulsed onto syngeneic dendritic cells.
- IFNg specific ELISPOT assays were performed with splenocytes restimulated in vitro with either the immunizing dominant peptide (or MART-1 peptide) or with Jurkat/AFP or Jurkat/MART transfected cell lines. Immunization with each hAFP peptide and subsequent restimulation with either peptide or Jurkat/AFP induced large numbers of AFP-specific IFNg-producing cells. Lymphocytes from PBS injected mice showed neither cytotoxicity nor IFNg production regardless of restimulation. Mice immunized with MART-1 27 . 35 peptide produced MART-1 specific responses but no AFP peptide responses.
- dendritic cells were prepared from bone marrow progenitors by differentiation in GM-CSF and IL-4 and were transduced with a recombinant AdV vector (AdVhAFP) that included hAFP cDNA.
- AdVhAFP AdV vector
- SEQ ID NO:l a recombinant AdV vector
- In vitro cultured dendritic cells were transduced in RPMI/2% FCS at an moi of 100. Transduction was carried out for two hours at 37°C. The dendritic cells were then washed and resuspended at 5 x 10 5 dendritic cells per 0.2 ml PBS per animal for injection. In all cases viability exceeded 95%.
- mice Two weeks after immunization, splenocytes from mice were restimulated with Jurkat cells stably transfected with hAFP (Jurkat/AFP) or with MART-1 (Jurkat/MART). The frequency of AFP-specific vs. MART-1 specific IFNg-release was determined by ELISPOT averaging three independent experiments where p ⁇ 0.02. Cytotoxicity was assayed against Jurkat/AFP and Jurkat/MART in a 5 hour 51 Cr-release assay. Next, HPLC and mass spectrometric identification was performed on the dominant peptides eluted from an HLA-A*0201 human hepatocellular carcinoma line. A summary of the results of these analyses are present in Table 2, below.
- HepG2 and Hep3B cells were washed three times with PBS before being incubated with 5 ml of citrate-phosphate buffer at pH 3.2 for 1 minute. The suspension was centrifuged (800x g for 5 minutes) and a total of 500 ml of cell-free supernatant was collected for each cell line. The materials were lyophilized to dryness and stored at -20° C. Lyophilized materials were redissolved in 30 ml of water/acetonitrile/triflouroacetic acid (W/A/TFA, 95/5/0.1 all by vol.).
- W/A/TFA water/acetonitrile/triflouroacetic acid
- This solution was pumped onto an analytical reverse phase HPLC column (Keystone Scientific C lg Betasil, 250 mm x 2 mm, 5 mm particle size, 100 A pore size) equilibrated in W/A/TFA, at a flow rate of 0.2 ml/min.
- Column eluate absorbance was monitored at 215 and 280 nm and 1 minute fractions were collected.
- the retention times of the synthetic peptides with amino acid sequences corresponding to the immunostimulatory peptides were obtained using the same separation gradient on a separate column.
- MALDI-TOF mass spectrometry was performed to analyze HPLC fractionated peptides acid-eluted from the AFP producing hepatocellular carcinoma cell lines HepG2 (HLA-A2 + ) and Hep3B (HLA-A2 ).
- a Voyager-REACTION PRODUCTS PerSeptive Biosystems, Framingham, MA
- Matrix Assisted Laser Deso ⁇ tion lonization/Time-Of-Flight (MALDI-TOF) instrument was used to acquire the mass spectra. The instrument uses a stainless-steel target, on which the samples are deposited and dried. All spectra were externally calibrated with insulin, resulting in mass accuracy typically within ⁇ 0.1 % .
- Lyophilized HPLC fractions were resuspended in 10 ⁇ l of 70% acetonitrile with 0.1 % TFA. One ⁇ l of this material was spotted along with 1 ⁇ l of the matrix a-cyano-4-hydroxycinnamic acid (Sigma, 10 mg/ml in 70% ACN/0.1 %TFA). Spectra were obtained by scanning from m/z 500-7000. The MALDI analysis of the HPLC fractions established that almost all fractions contained up to 20 different peptides in the mass range from 700 to 1500 Da, although frequently with a few dominating signals.
- the calculated (M+H) + of hAFP 542 . 55o was 975.5 and the retention time of the synthetic peptide with amino acids corresponding to hAFP ⁇ o, residues 542-550 of SEQ ID NO: 2, was 21.2 minutes. Furthermore, no signal at m/z of 975.5+1 was observed in samples with matrix alone and in HPLC fractions 18 to 22 from the Hep3B elution. Similarly, peaks with m/z corresponding to the calculated (M+H) + of hAFP, 58 . 166 , residues 158-166 of SEQ ID NO:2 and hAFP 325 .
- a method for preventing or for treating patients with hepatocellular carcinoma comprises selecting a suitable patient, such as an HLA-A*0201 + patient having AFP positive hepatocellular carcinoma.
- the patient is administered one or more than one peptides of the present invention.
- the peptides are administered in a sufficient dose and, preferably, the administration is repeated a plurality of times, to create an immune response to AFP, and thereby creates an immune response to the hepatocellular carcinoma.
- the peptides are a combination of hAFP 137 . ⁇ 45 , residues
- the one or more than one peptides are administered between 2 times and 5 times. In a particularly preferred embodiment, the peptides are administered 3 times. In another preferred embodiment, the one or more than one peptides are administered 3 times, at 2 week intervals.
- the peptides are administered intradermally, though other routes of administration are suitable as will be understood by those with skill in the art with reference to this disclosure.
- each of the one or more than one peptides are administered emulsified in 0.5 ml of Montanide ISA-51, such that when four peptides are combined, they are administered emulsified in a total of 2 ml of Montanide ISA-51.
- the emulsified peptide or peptides are divided into four equal does and each dose is administered in a separate site.
- the one or more than one peptides are administered in a dose of between about 50 ⁇ g and 2000 ⁇ g each.
- the one or more than one peptides are administered in a dose of between about 100 ⁇ g and 1000 ⁇ g each.
- the one or more than one peptides are administered in a dose of between about 500 ⁇ g.
- the method and compositions of the present invention were used to treat several patients with AFP positive/ A2.1 + hepatocellular carcinoma.
- Each of the patients were immunized with the four peptides hAFP, 37 ., 45 , residues 137-145 of SEQ ID NO:2; hAFP 158 . 166 , residues 158-166 of SEQ ID NO:2; hAFP 325 _ 334 , residues 325-334 of SEQ ID NO:2; and hAFP ⁇ .sso, residues 542-550 of SEQ ID NO:2, according to the this-method.
- the peptides were emulsified in 0.5 ml of Montanide ISA-51 and combined for a total of 2 ml.
- the emulsified peptides were divided into four equal doses and each dose was administered in a separate site.
- Peripheral T cell responses are measured by ELISPOT and tetramer assays. These trials show that the four AFP-derived peptides are immunogenic in vivo, even in patients whose levels of AFP in serum were extremely high before immunization.
- the first patient, designated AFP-A1 had a recurrent, unresectable AFP positive/ A2.1 + hepatocellular carcinoma. He was administered three immunizations of 100 ⁇ g each of the four peptides in Montanide ISA at two week intervals.
- AFP 542 -specific T cells could not be assessed by tetramer as an AFP ⁇ peptide tetramer could not be folded by the facility where these reagents are prepared.
- In vivo responses indicated clear recognition of hAFP 137 . 145 , residues 137-145 of SEQ ID NO:2; hAFP, 58 . 166 , residues 158-166 of SEQ ID NO:2; and hAFP 542 . 55 o, residues 542-550 of SEQ ID NO:2; and a trend towards recognition of hAFP 325 . 334 , residues 325-334 of SEQ ID NO:2 after the second and third immunization.
- AFP-A2 The second patient, designated AFP-A2 was a 70 yr old Caucasian male with a history of ethanol-induced liver cirrhosis, who was negative for both Hepatitis B and C. He presented with bloating and was found to have an 8 cm mass in the left lobe of his liver. His AFP level at presentation was 10,400 ng/ml. A liver biopsy revealed a well- differentiated hepatocellular carcinoma in a cirrhotic liver. He was begun on an experimental trial of the antifungal agent FV-462 but had disease progression and ototoxicity. Seven months after presentation, he was then begun on a combination of the four peptides hAFP 137 .
- a method for preventing or for treating patients with hepatocellular carcinoma comprises selecting a suitable patient, such as an HLA-A*0201 + patient having AFP positive hepatocellular carcinoma.
- the patient is administered dendritic cells pulsed with one or more than one peptide of the present invention.
- the dendritic cells are administered in a sufficient dose and, preferably, the administration is repeated a plurality of times, to create an immune response to AFP, and thereby creates an immune response to the hepatocellular carcinoma.
- the dendritic cells are pulsed with a combination of hAFP 137 . 145 , residues 137-145 of SEQ ID NO:2; hAFP 158 . 166 , residues 158-166 of SEQ ID NO:2;
- the dendritic cells are administered between 2 times and 5 times. In a particularly preferred embodiment, the dendritic cells are administered 3 times. In another preferred embodiment, the dendritic cells are administered 3 times, at 2 week intervals.
- the dendritic cells are administered intradermally, though other routes of administration are suitable as will be understood by those with skill in the art with reference to this disclosure.
- the dendritic cells are administered in a dose of between about 1x10 s and lxlO 8 .
- the dendritic cells are administered in a dose of between about lxlO 6 and lxlO 7 .
- the dendritic cells are administered in a dose of about 5xl0 6 .
- the dendritic cells are prepared from adherent, autologous peripheral blood mononuclear cells exposed for 1 week in tissue culture to granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin-4 (IL-4), according to techniques known to those with skill in the art.
- GM-CSF granulocyte-macrophage colony stimulating factor
- IL-4 interleukin-4
- Mononuclear cells are isolated from cells obtained from a single leukapheresis by Ficoll-Hypaque centrifugation and stored frozen in liquid nitrogen until used to generate dendritic cells.
- the thawed mononuclear cells are washed once in saline and plated at 2-4 x 10 7 cells/25cm 2 Costar flasks at a concentration of 2.5 - 5 x 10 6 viable cells/ml (RPMI 1640 + 5% heat-inactivated autologous serum + Gentamycin). After allowing adherence for 2 hours at 37°C, nonadherent cells are removed by washing with saline. Adherent cells are cultured in complete medium for 7 days in the presence of rhGM-CSF (800 U/ml) and rhIL-4 (500 U/ml). Clinical grade GM-CSF was provided by Immunex and IL-4 by Schering-Plough.
- subjects Before administering the full dose, subjects will receive a skin test with 1/100 of their dose in 0.1 ml of saline. After a 30 minute observation period, they will receive the full dose of AFP peptide-pulsed dendritic cells injected intradermally in 0.1 ml saline in the flank region below the axilla, or below or above the groin. Patients are monitored for 2 hours post-immunization. Preferrably, patients receive pretreatment with 50 mg diphenhydramine and 650 mg of Tylenol, both orally. EXAMPLE ffl
- a method for preventing or for treating patients with hepatocellular carcinoma comprises selecting a suitable patient, such as an HLA-A*0201 + patient having AFP positive hepatocellular carcinoma.
- a suitable patient such as an HLA-A*0201 + patient having AFP positive hepatocellular carcinoma.
- the patient is administered human AFP adenovirus-transduced dendritic cells.
- the dendritic cells are administered in a sufficient dose and, preferably, the administration is repeated a plurality of times, to create an immune response to AFP, and thereby creates an immune response to the hepatocellular carcinoma.
- the dendritic cells are administered between 2 times and 5 times. In a particularly preferred embodiment, the dendritic cells are administered 3 times. In another preferred embodiment, the dendritic cells are administered 3 times, at 2 week intervals.
- the dendritic cells are administered intradermally in the flank region below the axillae or the groin, though other routes of administration are suitable as will be understood by those with skill in the art with reference to this disclosure.
- the dendritic cells are administered in a dose of between about lxlO 5 and lxlO 8 .
- the dendritic cells are administered in a dose of between about lxlO 6 and lxlO 7 .
- the dendritic cells are administered in a dose of about 5xl0 6 .
- Mononuclear cells are isolated from a leukapheresis product by Ficoll-Hypaque centrifugation and stored in 10% DMSO/20% autologous serum.
- cells are thawed, washed once in PBS and plated at 2-4x10 7 cells/25cm 2 Costar flask at a concentration of 2.5-5xl0 6 viable cells/ml (RPMI 1640 + 5% heat-inactivated autologous serum). After allowing adherence for 2 hours at 37°C, nonadherent cells are gently removed by washing with PBS.
- Adherent cells are cultured in complete medium for 7 days in the presence of rhGM-CSF (800 U/ml) and rhIL-4 (500 U/ml).
- Clinical grade GM-CSF and IL-4 are provided by Schering-Plough.
- AdVhAFP is an El -deleted replication-deficient type 5 adenoviral vector in which the human AFP cDNA is driven by the CMV enhancer/promoter. Viral titers for each final viral production lot are provided based on both genomic DNA quantitation and infectious titer. A ratio in the product of viral particles to biologically active virus of less than 100: 1 are deemed acceptable.
- Patients are administered AdVhAFP transduced DC injected ID in 0.1 ml normal saline in the flank region below the axillae or the groin. Patients are monitored for 2 hours post-immunization. Preferrably, patients receive pretreatment with 50 mg diphenhydramine and 650 mg of Tylenol, both orally.
Abstract
Description
Claims
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18196600P | 2000-02-10 | 2000-02-10 | |
US181966 | 2000-02-10 | ||
US66025200A | 2000-09-12 | 2000-09-12 | |
US660252 | 2000-09-12 | ||
US66250500A | 2000-09-14 | 2000-09-14 | |
US662505 | 2000-09-14 | ||
PCT/US2001/004539 WO2001058922A2 (en) | 2000-02-10 | 2001-02-12 | Method and compositions for treating hepatocellular cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1253930A2 true EP1253930A2 (en) | 2002-11-06 |
EP1253930A4 EP1253930A4 (en) | 2003-05-21 |
Family
ID=27391498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01910587A Ceased EP1253930A4 (en) | 2000-02-10 | 2001-02-12 | Method and compositions for treating hepatocellular cancer |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1253930A4 (en) |
JP (1) | JP3876162B2 (en) |
KR (1) | KR100482920B1 (en) |
CN (1) | CN1255427C (en) |
AU (1) | AU2001238179A1 (en) |
HK (1) | HK1046853A1 (en) |
WO (1) | WO2001058922A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100985914B1 (en) * | 2006-12-13 | 2010-10-08 | 주식회사 바이오리더스 | Cell Surface Expression Vector for liver Cancer Specific Antigen Alpha-fetoprotein and Microorganism Transformed by Thereof |
WO2008113970A2 (en) * | 2007-03-16 | 2008-09-25 | Ucl Business Plc | Peptides |
KR100900742B1 (en) * | 2007-05-17 | 2009-06-08 | 크레아젠 주식회사 | Animal Models Carrying Tumors Expressing Human Liver Cancer-Specific Antigen and Method for Analyzing Prevention and Treatment Efficacy of Dendritic Cells-Derived Immunotherapeutics Using the Above |
US8541543B2 (en) * | 2007-11-20 | 2013-09-24 | Academia Sinica | Peptides specific for hepatocellular carcinoma cells and applications thereof |
SG10201913158PA (en) * | 2015-04-03 | 2020-02-27 | Eureka Therapeutics Inc | Constructs targeting afp peptide/mhc complexes and uses thereof |
CN113072636A (en) * | 2020-01-06 | 2021-07-06 | 香雪生命科学技术(广东)有限公司 | T cell receptor for identifying AFP and its code sequence |
CN113321725A (en) * | 2020-02-28 | 2021-08-31 | 香雪生命科学技术(广东)有限公司 | T cell receptor for identifying AFP |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1226551B (en) * | 1988-07-29 | 1991-01-24 | Sclavo Spa | IMMUNOLOGICALLY ACTIVE SYNTHETIC PEPTIDE CAPABLE OF INDUCING THE PRODUCTION OF ANTIBODIES WITH HIGH SPECIFICITY TOWARDS ALPHA-PHETOPROTEIN AND THEIR USE IN THE DIAGNOSTIC FIELD |
EP0805687A4 (en) * | 1995-01-24 | 2000-05-31 | Robert A Murgita | Recombinant human alpha-fetoprotein and uses thereof |
CN1739791A (en) * | 1997-02-13 | 2006-03-01 | 加利福尼亚大学董事会 | Prevention and treatment of hepatocellular cancer |
-
2001
- 2001-02-12 EP EP01910587A patent/EP1253930A4/en not_active Ceased
- 2001-02-12 CN CNB018047580A patent/CN1255427C/en not_active Expired - Fee Related
- 2001-02-12 WO PCT/US2001/004539 patent/WO2001058922A2/en not_active Application Discontinuation
- 2001-02-12 KR KR10-2002-7010174A patent/KR100482920B1/en not_active IP Right Cessation
- 2001-02-12 JP JP2001558069A patent/JP3876162B2/en not_active Expired - Fee Related
- 2001-02-12 AU AU2001238179A patent/AU2001238179A1/en not_active Abandoned
-
2002
- 2002-11-18 HK HK02108331.9A patent/HK1046853A1/en unknown
Non-Patent Citations (2)
Title |
---|
BUTTERFIELD L H ET AL: "T cell responses to HLA-A* 0201-restricted peptides derived from human ÄalphaÜ fetoprotein" JOURNAL OF IMMUNOLOGY 15 APR 2001 UNITED STATES, vol. 166, no. 8, 15 April 2001 (2001-04-15), pages 5300-5308, XP002235963 ISSN: 0022-1767 * |
See also references of WO0158922A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2001058922A2 (en) | 2001-08-16 |
CN1255427C (en) | 2006-05-10 |
WO2001058922A9 (en) | 2002-10-17 |
EP1253930A4 (en) | 2003-05-21 |
HK1046853A1 (en) | 2003-01-30 |
KR20020073203A (en) | 2002-09-19 |
JP2003522195A (en) | 2003-07-22 |
AU2001238179A1 (en) | 2001-08-20 |
CN1398187A (en) | 2003-02-19 |
JP3876162B2 (en) | 2007-01-31 |
KR100482920B1 (en) | 2005-04-14 |
WO2001058922A3 (en) | 2002-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060286075A1 (en) | Method and compositions for treating hepatocellular cancer | |
US11707512B2 (en) | Cancer vaccine composition | |
Butterfield et al. | T cell responses to HLA-A* 0201-restricted peptides derived from human α fetoprotein | |
AU2006277295B2 (en) | Glypican-3 (GPC3)-derived tumor rejection antigenic peptides useful for HLA-A2-positive patients and pharmaceutical comprising the same | |
Mayordomo et al. | Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. | |
JP4926714B2 (en) | Proteins belonging to the BCL-2 family and fragments thereof, and their use in cancer patients | |
US7994276B2 (en) | Composition of tumour-associated peptides and related anti-cancer vaccine | |
Ishida et al. | Dendritic cells transduced with wild‐type p53 gene elicit potent anti‐tumour immune responses | |
EP3263585B1 (en) | Foxm1 peptide and medicinal agent comprising the same | |
EP2470200B1 (en) | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer | |
EP3148566B1 (en) | Synthetic long peptides (slp) for therapeutic vaccination against hepatitis b virus infection | |
BR112020025764A2 (en) | neoantigens and their uses | |
KR20210040355A (en) | Neo antigen and its use | |
JP5065273B2 (en) | HLA-A24 molecule binding peptide derived from KIF | |
WO2001058922A2 (en) | Method and compositions for treating hepatocellular cancer | |
JP4780540B2 (en) | Survivin-derived cancer antigen peptide | |
WO2007120603A2 (en) | Immunogenic bcr-abl peptides and methods of use thereof | |
KR20210018295A (en) | Composition for inducing an immune response | |
Minev | Melanoma vaccines | |
WO2004012685A2 (en) | Shed antigen vaccine with dendritic cells adjuvant | |
RU2805196C2 (en) | Neoantigens and their application | |
EP2421891A1 (en) | Immunogenic epitopes of ngep antigen | |
WO2007047763A2 (en) | Bcr-abl vaccines and methods of use thereof | |
WO2001098363A2 (en) | Peptides for use in the immunotherapy of renal cell carcinoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020724 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20030408 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20061230 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1046853 Country of ref document: HK |